NIPP1 is a ubiquitously expressed nuclear protein that functions both as a regulator of protein Ser/Thr phosphatase-1 and as a splicing factor. The N-terminal part of NIPP1 consists of a phosphothreonine-interacting Forkhead-associated (FHA) domain. We show here that the FHA domain of NIPP1 interacts in vitro and in vivo with a TP dipeptide-rich fragment of the splicing factor SAP155/SF3b 155 , a component of the U2 small nuclear ribonucleoprotein particle. The NIPP1-SAP155 interaction was entirely dependent on the phosphorylation of specific TP motifs in SAP155. Mutagenesis and competition studies revealed that various phosphorylated TP motifs competed for binding to the same site in the FHA domain. The SAP155 kinases in cell lysates were blocked by the Ca 2؉ chelator EGTA and by the cyclin-dependent protein kinase inhibitor roscovitine. The phosphorylation level of SAP155 was dramatically increased during mitosis, and accordingly the activity of SAP155 kinases was augmented in mitotic lysates. We discuss how the interaction between NIPP1 and SAP155 could contribute to spliceosome (dis)assembly and the catalytic steps of splicing.
Spliceosomes catalyze the removal of intronic sequences from primary transcripts (pre-mRNAs) in two consecutive transesterification reactions (1) (2) (3) . Their major components are the U1, U2, U5, and U4/U6 small nuclear ribonucleoprotein particles (snRNPs), 1 which consist of small nuclear RNAs and a set of snRNP proteins. These snRNPs are recruited from nuclear storage/assembly sites known as the splicing factor compartments or speckles, and their assembly on pre-mRNAs occurs in a stepwise manner. According to a recent model of spliceosome assembly (2) , U1 snRNP and U4/U6⅐U5 tri-snRNP first contact the 5Ј splice site. Subsequently U2 snRNP binds stably to the intronic branch site region. The creation of splicing-competent spliceosomes also depends on the recruitment of numerous nonsnRNP-associated splicing factors and requires multiple, ordered rearrangements between spliceosomal components.
Substantial evidence implicates reversible protein phosphorylation in both spliceosome (dis)assembly and splicing catalysis (2, 4) . For example, the SR family of splicing factors contain a domain that is rich in Arg/Ser dipeptides, and the phosphorylation of these motifs by specific "SR" kinases has been shown to modulate the interaction of SR proteins with other splicing factors and with RNA during spliceosome assembly (5) . The shuttling of SR proteins between the speckles and the spliceosomes and the dispersion of SR proteins from the speckles during mitosis is also controlled by phosphorylation (6 -8) . The splicing factor SF1/BBP, which interacts with U2AF65 in an early step of spliceosome assembly, is a substrate for phosphorylation by protein kinase G (9) . The phosphorylation of SF1/ BBP inhibits its interaction with U2AF65 and blocks splicing complex formation. A role for protein phosphatases in pre-mRNA splicing has also been firmly established. The protein Ser/Thr phosphatase PP2C␥ is required for an early step of spliceosome assembly (10) , while okadaic acid-sensitive protein phosphatases, such as PP2A, appear to function during splicing catalysis (11) . The adenovirus E4-ORF4 protein induces the dephosphorylation of host cell SR proteins by the recruitment of PP2A, which alleviates the inhibition of adenovirus IIIa pre-mRNA splicing by the SR proteins (12, 13) .
The only splicing factor that is known to be phosphorylated during splicing catalysis is SAP155, also named SF3b 155 (14) . This protein is one of the five subunits of the SF3b complex that, together with the SF3a protein complex, binds to a 12 S precursor of U2 snRNP and thereby converts it to the 17 S form that is recruited to the spliceosomes (15, 16) . SAP155 contacts pre-mRNA on both sites of the branch site early in spliceosome assembly and is thus positioned near the spliceosome catalytic center. SAP155 also binds to U2AF35 (17) , U2AF65 (17) , cyclin E (18) , and the SF3b components SAP130 and p14 (15) (16) (17) , although it appears unlikely that these proteins all interact simultaneously with SAP155. It has been suggested that the phosphorylation of SAP155 during splicing catalysis somehow affects its association with RNA or with associated splicing factors (14) .
Our interest in the control of pre-mRNA splicing by protein (de)phosphorylation stems from work on the nuclear protein NIPP1 (38.5 kDa). Originally we identified NIPP1 as an inhibitory subunit of a nuclear species of the Ser/Thr-specific protein phosphatase PP1, hence its name nuclear inhibitor of PP1 (19, 20) . The heterodimeric complex between NIPP1 and PP1 is inactive, but a protein phosphatase activity is revealed either by the binding of NIPP1 to RNA (21) or by the phosphorylation of NIPP1 on specific Ser/Thr or Tyr residues (21, 22) . NIPP1 is enriched in the nuclear speckles (23, 24) but is also a component of the spliceosomes (25) . In nuclear extracts NIPP1 is required for spliceosome assembly, and pre-mRNA splicing by these extracts is blocked when the recruitment of NIPP1 to the spliceosomes is prevented. Remarkably, the function of NIPP1 in spliceosome assembly is unrelated to its ability to bind PP1 or RNA, indicating that NIPP1 can act independently as a splicing factor and as a protein phosphatase regulator.
The N-terminal third of NIPP1 largely consists of a Forkhead-associated (FHA) domain (26) , a phosphothreonine-binding module that is also present in many other, mostly nuclear proteins (27, 28) . The FHA domain is required for the targeting of NIPP1 to the speckles (24) and to the spliceosomes (25) . We have previously shown that the FHA domain of NIPP1 interacts with CDC5L, a regulator of pre-mRNA splicing and mitotic entry (26) . Although CDC5L is also present in the speckles, the targeting of NIPP1 to the speckles could at most be partially accounted for by its association with CDC5L since some speckles contained NIPP1 but no CDC5L. These data suggested that the FHA domain of NIPP1 has additional binding partners. Accordingly we show here that the FHA domain of NIPP1 also binds to the splicing factor SAP155 in vitro and in vivo. We furthermore demonstrate that the interaction between both components is controlled by multisite phosphorylation and is cell cycle-regulated. ) coupled to keyhole limpet hemocyanin were used for the generation of rabbit polyclonal antibodies. The antibodies were affinity-purified on the bovine serum albumin-coupled peptides linked to CNBr-activated Sepharose 4B. Monoclonal LexA tag and polyclonal His tag antibodies were purchased from Santa Cruz Biotechnology. Rabbit and mouse secondary antibodies were obtained from Dako. Human cyclin E-Cdk2 was produced by baculovirus expression in High Five TM cells (26) . Cyclin B-Cdk1, purified from X. laevis oocytes, was a kind gift from Drs. J. Goris and I. Stevens. The catalytic subunit of PP1 was prepared from rabbit skeletal muscle (26) . Other key materials were obtained from MBI Fermentas GmbH (restriction enzymes and Pwo DNA polymerase), Sigma (Colcemid), Alexis Biochemicals (roscovitine), Calbiochem (microcystin-LR), Roche Diagnostics (endoproteinase Lys-C and Asp-N), and the Computer Cell Culture Center (HeLa cell nuclear extracts).
EXPERIMENTAL PROCEDURES

Materials-Synthetic
Expression Vectors and Yeast Dual-hybrid Screening-Constructs for the bacterial expression of polyhistidine-tagged SAP155-(1-491) and SAP155-(223-322) were generated by subcloning of the corresponding PCR fragments of SAP155 in the pET16b plasmid. Vectors for the bacterial expression of GST-or polyhistidine-tagged NIPP1-(1-142) or NIPP1-(1-142) mutant (S68A/R69A/V70A/H71A) were described before (24, 26) . Point mutations were introduced by the QuikChange TM sitedirected mutagenesis method of Stratagene. For the yeast two-hybrid screening, NIPP1-(1-142) and NIPP1-(225-351) were cloned in-frame with the LexA protein (which includes a DNA-binding protein) in the pEG202 plasmid (26) . The NIPP1-(1-142) construct was used as bait for the screening of a HeLa cell cDNA library subcloned in the pJG4-5 plasmid in-frame with the B42 activation domain. For the mapping of the interaction domain between SAP155 and NIPP1-(1-142) the SAP155 fragments 1-222, 323-491, 277-376, 201-301, 257-322, 257-301, and 381-491 were subcloned in-frame with the B42 activation domain in the pJG4-5 plasmid. The ␤-galactosidase activities were quantified by a liquid culture assay (CLONTECH yeast protocols handbook).
Co-immunoprecipitations and GST Pull-downs-Liver nuclear extracts, used for pull-downs with GST-NIPP1-(1-142), were prepared as described by Jagiello et al. (20) except that the extracts were finally diluted in buffer without salt and Triton X-100. The extracts were prepared in the absence or presence of protein phosphatase inhibitors (0.5 M microcystin-LR, 20 mM NaF, and 1 mM sodium vanadate). An aliquot of the extracts prepared without phosphatase inhibitors was preincubated for 10 min at 30°C with PP1 (60 nM). For some pull-down assays recombinant SAP155-(223-322) (5 g) was first phosphorylated by an overnight incubation at 30°C in 30 l of a buffer containing 20 mM Tris-HCl at pH 7.4, 1 mM dithiothreitol, 4 mM magnesium acetate, 1 mM ATP, and 0.12 g cyclin E-Cdk2. Immunoprecipitations, GST pull-downs, and Western analyses were performed as described previously (20, 26) .
Splicing Assays-A capped ␤-globin pre-mRNA fragment, comprising exon 1 through the BamHI site in exon 2, was synthetized in the presence of [␣-32 P]GTP. This primary transcript was used as a substrate for splicing in HeLa cell nuclear extracts (25) . Immunoprecipitations during the splicing reactions were done as described previously (25) .
Determination of Cyclin E-Cdk2 Phosphorylation Sites-Radioactively phosphorylated SAP155-(223-322) (25 g) was precipitated with 20% (w/v) trichloroacetic acid. The pellet was washed once with 20% trichloroacetic acid and twice with diethyl ether and then dissolved in 100 l of a buffer containing 20 mM Tris at pH 8.5 and 0.01% (w/v) sodium dodecylsulfate. After an overnight incubation with 0.5 g of endoproteinase Lys-C or endoproteinase Asp-N at 37°C in a total volume of 200 l, the digest was applied to a reversed-phase column (RPC C2/C18 SC2.1/10 from Amersham Biosciences) equilibrated in 0.1% (v/v) trifluoroacetic acid. The retained peptides were eluted with a linear gradient of acetonitrile (0 -70%) in 0.1% trifluoroacetic acid. The radioactive fractions of the endoproteinase Asp-N digest were reapplied to the same reversed-phase column, this time equilibrated in water. The retained peptide was eluted with a linear gradient of ammonium acetate (0 -10 mM) at pH 6.5. The radioactive peptides were sequenced as detailed before (21) . The phosphopeptides obtained from the endoproteinase Lys-C digest were 
RESULTS
Phosphorylation-dependent Interaction between NIPP1
and SAP155-The FHA domain of NIPP1 (residues 1-142) was used as bait in a yeast two-hybrid screening of a HeLa cell library. Of 41 positive clones, 15 clones encoded three different fragments of the splicing factor SAP155 (Fig. 1B) . These SAP155 fragments interacted with the FHA domain with an affinity similar to CDC5L-(258 -614) as determined by liquid ␤-galactosidase assays. However, the SAP155 fragments did not interact with the C-terminal domain of NIPP1 or with Sds22, an unrelated regulator of protein phosphatase-1 ( Fig.  1B and not shown).
The SAP155 fragments that interacted with NIPP1 all comprised (a part of) the TP dipeptide-rich domain in the N-terminal third of SAP155 (Fig. 1, A and B) . The largest SAP155 fragment (residues 1-491) was also the best interactor of the FHA domain. However, deletion of the N-terminal 208 residues, which lie outside the TP-rich domain, only marginally reduced the interaction with NIPP1. Fragments of the TP-rich domain interacted less well with NIPP1-(1-142) than did the intact TP-rich domain, and generally the strength of the interaction decreased with the size of the SAP155 fragments. Interestingly, the non-overlapping fragments SAP155-(223-322) and SAP155-(323-491) both interacted with NIPP1-(1-142), indicating that the TP-rich domain of SAP155 contains multiple, independent interaction sites for NIPP1.
To further explore the relevance of the interaction between NIPP1 and SAP155, we performed co-precipitation experiments. Following a preincubation of nuclear extracts from rat liver ( Fig. 2A ) or HeLa cells ( Fig. 2B ) with a bacterially expressed GST fusion of NIPP1-(1-142), a GST pull-down of the fusion protein caused a co-precipitation of SAP155. Likewise, the immunoprecipitation of NIPP1 from HeLa cell nuclear extracts was associated with a co-immunoprecipitation of SAP155 (Fig. 2B ). Various observations indicated that the SAP155-NIPP1 interaction was critically dependent on the phosphorylation of SAP155. Thus, when the FHA domain was mutated (S68A/R69A/V70A/H71A) in residues that are part of a conserved phosphate-binding loop (29) , no co-precipitation of SAP155 was observed (Fig. 2, A and B) . This mutated FHA domain also failed to interact with SAP155 in a yeast dualhybrid assay (not shown). Pull-down experiments furthermore revealed that the co-precipitation of GST-NIPP1-(1-142) and SAP155 was increased when the liver nuclear extracts were prepared in the presence of a mixture of protein phosphatase inhibitors, while their co-precipitation was nearly completely abolished after a preincubation of the extracts with PP1 ( Fig.  2A) . On the other hand, an interaction between NIPP1 and SAP155 in HeLa cell nuclear extracts was only detected after a preincubation of the extracts with MgATP, suggesting that the endogenous SAP155 had been completely dephosphorylated during the preparation and/or storage of the extracts (Fig. 2B) . In this respect, it is worthy of note that the nuclear extracts from HeLa cells were at least 10-fold more concentrated than those from rat liver, which favors a faster and more complete dephosphorylation by endogenous protein phosphatases.
Mapping of the Phosphorylation Sites That Confer Binding of SAP155-(223-322) to NIPP1-
The TP-rich domain of SAP155 (Fig. 1C) has been shown to be a substrate for phosphorylation by cyclin E-Cdk2 (18). We indeed found that SAP155-(223-322) and SAP155-(1-491) are excellent substrates for in vitro phosphorylation by cyclin E-Cdk2 as well as cyclin B-Cdk1 ( Fig. 3A and not shown). Moreover, a co-precipitation of GST-NIPP1-(1-142) and SAP155-(223-322) was dependent on the prior phosphorylation of the SAP155 fragment by cyclin E-Cdk2 or cyclin B-Cdk1 (Fig. 3B) . Again a co-precipitation of both components was not seen when the FHA domain was mutated in its phosphate-binding loop.
The above results indicated that the binding of SAP155 to NIPP1 might be dependent on the phosphorylation of TP motifs. We have subsequently studied in some detail the role of the TP dipeptide motifs in the interaction between NIPP1-(1-142) and SAP155-(223-322), which only contains 13 of the 29 TP motifs that are present in the TP-rich domain of SAP155. The involvement of each of the 13 TP motifs of SAP155-(223-322) in the interaction with NIPP1-(1-142) was studied by site-directed mutagenesis. Unexpectedly, not one of the 13 threonine to alanine point mutations completely abolished the interaction of SAP155-(223-322) with NIPP1-(1-142) as measured in a dual-hybrid assay (Fig. 4A) , although some of the point mu- The numbers represent the ␤-galactosidase activity (means Ϯ S.E., n ϭ 5) as derived from a liquid culture assay. The asterisks refer to the SAP155 fragments that were originally picked up during the twohybrid screening. The SAP155 fragments that showed a strong interaction with NIPP1-(1-142) in the two-hybrid assay are indicated in black. Weakly interacting SAP155 fragments are indicated in gray. C, primary structure of the TP-rich domain of human SAP155. The TP dipeptide motifs are indicated in bold, and established in vitro phosphorylation sites for cyclin E-Cdk2 are underlined. The numbers on the right refer to amino acids of human SAP155.
FIG. 2. Phosphorylation-dependent interaction of SAP155 and NIPP1 in nuclear extracts.
A, co-precipitation of SAP155 and (mutated) GST-NIPP1-(1-142) from rat liver nuclear extracts. The extracts were prepared in the absence or presence of a mixture of inhibitors of protein phosphatases. An aliquot of the extracts without phosphatase inhibitors was also preincubated with PP1. The SAP155 that co-sedimented with the GST fusion proteins was visualized by Western blotting with SAP155 antibodies. B, HeLa cell nuclear extracts were incubated at 30°C for the indicated times with MgCl 2 (4 mM) and ATP (0.5 mM) to allow phosphorylation of the endogenous SAP155. During the subsequent immunoprecipitation with NIPP1 antibodies (upper panel) or pull-down with (mutated) GST-NIPP1-(1-142) (lower panel), further protein (de)phosphorylation was stopped by the addition of 10 mM EDTA, 1 M microcystin-LR, and 1 mM orthovanadate. IP, immunoprecipitation.
tants showed a significantly decreased interaction. These data suggested that the SAP155-(223-322)-NIPP1 interaction was controlled by multisite phosphorylation.
To map the set of phosphorylation sites in SAP155-(223-322) that determine its interaction with NIPP1, we have identified phosphorylation sites of cyclin E-Cdk2 by the sequencing of proteolytically derived phosphopeptides (see "Experimental Procedures"). Three phosphorylation sites were identified as Thr 244 , Thr 248 , and Thr 313 . All three sites are followed by a proline, although none of the sites contains a basic residue at position ϩ3 (Fig. 1C) as is commonly seen for Cdk phosphorylation sites. The mutation of all three sites into an alanine decreased the in vitro phosphorylation of SAP155-(223-322) by cyclin E-Cdk2 by only 79% (Fig. 5A) but completely abolished the ability of SAP155-(223-322) to bind to GST-NIPP1-(1-142) in vitro (Fig. 5B) . Also, the triple mutant did not interact with the FHA domain of NIPP1 in a dual-hybrid assay (Fig. 4A) , although this mutant was expressed well (Fig. 4B) . The mutation of two of the three mapped phosphorylation sites only partially abolished the interaction of SAP155-(223-322) with NIPP1-(1-142) (Fig. 4A) . Importantly, the mutation of Thr 244 , Thr 248 , and Thr 313 did not abolish the binding of a larger SAP155 fragment (SAP155-(1-491) ) to NIPP1 as determined by pull-downs with GST-NIPP1-(1-142) or by two-hybrid assays (not shown). The latter data are in accordance with our findings that the fragment of the TP-rich domain that is Cterminal to residues 223-322 also harbors one or more binding sites for NIPP1 (Fig. 1B) .
SAP155-derived Phosphopeptides Disrupt
Complexes with NIPP1-The data in Fig. 4 suggested that SAP155-(223-322) acquires a binding site for NIPP1 after phosphorylation of Thr 244 , Thr 248 , or Thr 313 . To distinguish between common or distinct NIPP1 binding sites for these phosphothreonines, we have performed competition studies with synthetic SAP155-derived phosphopeptides. Fig. 5C shows that the synthetic peptide SAP155-(308 -318), with Thr 313 phosphorylated, inhibited the binding of SAP155-(223-322) to GST-NIPP1-(1-142) in a concentration-dependent way. No competition was seen with the non-phosphorylated peptide. Combined with our observations that the FHA domain that was mutated in the established phosphate-binding loop failed to bind SAP155 (Figs. 2 and 3) , 
Interaction of NIPP1 with Phosphorylated SAP155
these data strongly indicate that the FHA domain only contains a single phosphothreonine binding site. Another phosphopeptide, SAP155-(239 -253), with Thr 244 and Thr 248 phosphorylated, was a less efficient competitor (not shown), suggesting that these phosphothreonines bind to NIPP1 with a lower affinity than does phospho-Thr 313 . The phosphopeptide SAP155-(308 -318) (Thr(p) 313 ) also disrupted the interaction between NIPP1 and full-length SAP155 in nuclear extracts in a concentration-and phosphorylation-dependent manner (Fig. 5C ). These data suggested that all NIPP1 binding sites of SAP155, including those outside residues 223-322 (Fig. 1B) , interact with the same fragment of NIPP1. Importantly, SAP155-(308 -318) (Thr(p) 313 ) also dissociated a complex of GST-NIPP1-(1-142) and phosphorylated CDC5L (not shown), indicating that SAP155 and CDC5L compete for the same binding site in the FHA domain of NIPP1.
Since the phosphopeptide SAP155-(308 -318) (Thr(p) 313 ) disrupted the interaction between the FHA domain of NIPP1 and its ligands in nuclear extracts (Fig. 5C) , we have explored whether this peptide also interfered with the recruitment of NIPP1 to the spliceosomes and with pre-mRNA splicing. Surprisingly, while the addition of the FHA domain of NIPP1 blocked the co-immunoprecipitation of endogenous NIPP1 and radioactively labeled ␤-globin pre-mRNA, the addition of the phosphopeptide did not have this effect (Fig. 6A) . Likewise, the FHA domain blocked pre-mRNA splicing of the ␤-globin pre-mRNA fragment, but the SAP155-derived phosphopeptide did not interfere with splicing (Fig. 6B) . Thus, the recruitment of NIPP1 to the spliceosomes is independent of the recruitment of SAP155 and CDC5L.
SAP155 Is Hyperphosphorylated during Mitosis-Since SAP155 acquired binding sites for NIPP1 after phosphorylation by an interphase Cdk (cyclin E-Cdk2) as well as by a mitotic Cdk (cyclin B-Cdk1), we have examined whether the phosphorylation of SAP155 is regulated in a cell-cycle dependent manner. Pull-down assays with GST-NIPP1-(1-142) showed a huge increase in the amount of SAP155 that cosedimented from lysates prepared from mitotically arrested COS-1 cells (Fig. 7A ) or HeLa cells (not shown) as compared with that from asynchronously dividing (interphase) cells. The increased binding of SAP155 in mitotic extracts was not due to an increased total concentration of SAP155 (Fig. 7B) and required an FHA domain with an intact phosphate-binding loop (Fig. 7A) , suggesting that it was mediated by an increased phosphorylation of SAP155. On the other hand, the amount of SAP155 that co-immunoprecipitated with NIPP1 was the same in interphase and mitotic lysates (Fig. 7C) . Collectively these data suggested that SAP155 and NIPP1 are part of the same macromolecular complex during interphase as well as during mitosis, but during mitosis, SAP155 is hyperphosphorylated on sites that mediate binding to NIPP1. It remains to be examined whether the direct interaction between SAP155 and NIPP1 is actually increased during mitosis or whether SAP155 is merely primed for binding to NIPP1 after mitosis.
Characterization of SAP155 Kinases-To gain additional insight into the nature of the protein kinase(s) that phosphorylate SAP155, we have examined the effect of protein kinase inhibitors on the phosphorylation of SAP155-(1-491) by cell lysates from asynchronously dividing and mitotically arrested cells. We noted that the SAP155-(1-491) kinase activity in lysates from mitotically arrested cells (Fig. 8B) was about 2-fold higher than that in lysates from asynchronously dividing cells (Fig. 8A) as expected from the increased binding of SAP155 to GST-NIPP1 in mitotic lysates (Fig. 7A) . Inhibitors of protein kinase C (bisindolylmaleimide I), protein kinase A (protein kinase A inhibitory peptide), mitogen-activated protein kinases (PD98059 and PD1693168), glycogen synthase kinase 3 (LiCl), phosphatidylinositol 3-kinase (wortmannin), and protein kinase CK2 (heparin) did not measurably affect the SAP155 kinase activity (not shown). However, the Ca 2ϩ chelator EGTA blocked the SAP155 kinase activity in lysates from asynchronously dividing and mitotically arrested cells by about 90 and 70%, respectively (Fig. 8) . On the other hand, roscovitine, an established Cdk inhibitor (30) , decreased the SAP155 kinase activity in mitotic and interphase lysates by about 50 and 30%, respectively. The higher contribution of a roscovitinesensitive kinase in mitotic lysates is in accordance with a role for Cdk1 as a major mitotic SAP155 kinase (see "Discussion"). The addition of both EGTA and roscovitine blocked nearly all the SAP155 kinase activity in cell lysates (Fig. 8) . Importantly, EGTA and roscovitine also decreased the binding of SAP155-(1-491) to NIPP1 in pull-down assays (Fig. 8B, inset) , indicating that the inhibited kinase(s) catalyzes the phosphorylation of sites in SAP155 that control its affinity for NIPP1.
The N-terminal domain of SAP155 contains two putative 
phosphorylation sites (Thr 125 and Ser 217 ) for the Ca 2ϩ -and calmodulin-dependent protein kinase II. Since EGTA efficiently blocked the phosphorylation of SAP155 by cell lysates (Fig. 8) , we have explored whether this protein kinase could contribute to the SAP155-NIPP1 interaction. We found that recombinant Ca 2ϩ -calmodulin-dependent protein kinase II was indeed an efficient SAP155 kinase in vitro but did not endow SAP155-(1-491) with a high affinity binding site for NIPP1 (not shown). Thus, the Ca 2ϩ -dependent phosphorylation of SAP155 in cell lysates is either mediated by another Ca 2ϩ -dependent protein kinase or by a protein kinase that is activated by a Ca 2ϩ -dependent process.
DISCUSSION
Binding Determinants of the FHA Domain of NIPP1-FHA domains have been identified as phosphoprotein binding modules, but the exact determinants of their interaction are only partially known (27, 29) . They bind preferentially to phosphothreonine-containing peptides, although one of the FHA domains of Rad53 has also been shown to bind to peptides with a phosphotyrosine (31) . Studies using peptide library screening revealed that motif selection typically extends for three residues N-terminal and C-terminal to the phosphothreonine. Of particular importance for the binding specificity of various FHA domains is the residue in the Thr(p) ϩ3 position (27, 29) . However, this may not be true for the FHA domain of NIPP1 since the three mapped phosphothreonines that mediate binding of SAP155 to NIPP1 are followed by a different residue (Ala, Ser, or Thr) at position ϩ3 (Fig. 1C) . On the other hand, these phosphothreonines are all three followed by a proline, which therefore may represent an important determinant of binding selectivity. This view is in accordance with previous findings that the interaction of NIPP1 with CDC5L is also mediated by a TP-rich domain (26) . The domain of SAP155 that interacts with NIPP1 (this work) contains, in addition to multiple TP motifs, also various RWD and GH motifs (14) . However, it seems unlikely that these motifs are important determinants for the interaction with NIPP1 since such motifs are not present in CDC5L.
The binding specificity of the FHA domain of NIPP1 is most similar to that of the Ki-67 antigen. The latter FHA domain binds to the nucleolar RNA-binding protein NIFK, and this interaction involves two phosphorylated TP motifs (32) . However, the mutation of only one of these TP motifs abolished the binding of NIFK to Ki-67 in a two-hybrid assay. This is different for the SAP155-(223-322)-NIPP1 interaction, which was only abolished after mutation of at least three Cdk2-phosphorylated TP motifs (Fig. 4) , pointing to the presence of multiple, independent binding sites for NIPP1. It seems likely that these TP motifs all interact with NIPP1 in a similar or identical manner since the SAP155-NIPP1 complex could be completely disrupted with a synthetic peptide that contained only one of these (phosphorylated) TP motifs (Fig. 5C) . That the FHA domain of NIPP1 only has a single phosphothreonine binding site is also in accordance with findings that mutation of residues 68 -71, which are part of a phosphate-binding loop that is conserved in all FHA domains, completely abolished the interaction with SAP155 (Fig. 3 ).
An intriguing question concerns the need for multiple independent and mutually exclusive NIPP1 binding sites in SAP155. It is possible that multiple binding sites increase the stability of the NIPP1-SAP155 complex by decreasing the rate of dissociation. It can also be envisaged that the NIPP1 binding sites are not equally accessible in vivo, e.g. because their phosphorylation is differently controlled or because binding of NIPP1 is hampered by competing ligands.
Both SAP155 (3, 15) and CDC5L (33) are subunits of large protein complexes. Our finding that the binding of NIPP1 to these proteins is phosphorylation-dependent explains why NIPP1 has previously not been recognized as a subunit of these complexes since no precautions were taken to prevent dephosphorylation reactions during the purification procedure.
SAP155 Kinases-Various lines of evidence point to a role of cell cycle-regulated protein kinases in the control of the SAP155-NIPP1 interaction in mammalian cells. Thus, cyclin B-Cdk1 and Cyclin E-Cdk2 acted as SAP155 kinases in vitro (Fig. 3) , and roscovitine, an established Cdk inhibitor, inhibited the SAP155 kinase activity in cell lysates (Fig. 8) . Also, cyclin E-Cdk2 has been shown to directly associate with the TP-rich domain of SAP155 (18), and the SAP155 kinase activity in cell lysates was doubled during mitosis when Cdk1 is activated (Fig. 8) . Interestingly, the splicing factor CDC5L, another interactor of the FHA domain of NIPP1 (26) , has also been identified as a mitotic phosphoprotein (34) .
It is intriguing that roscovitine also inhibited the SAP155 kinase activity in interphase extracts when Cdk2 is only transiently active. This could indicate that other interphase Cdks are also implicated in the phosphorylation of SAP155. An obvious candidate would be Cdk7, which is also nuclear and is sensitive to inhibition by roscovitine (30) . On the other hand, the SAP155 kinase activity was only partially inhibited by roscovitine (Fig. 8) , indicating that the TP domain of SAP155 can also be phosphorylated by a cyclin-independent protein kinase(s). This conclusion is in accordance with the report that a large fraction of the protein kinase activity in SAP155 immunoprecipitates is insensitive to a Cdk inhibitor (18) . We found that the SAP155 kinase activity in cell lysates is efficiently inhibited by EGTA (Fig. 8) , suggesting that SAP155 may be a substrate for a Ca 2ϩ -dependent protein kinase. Two members of the family of Ca 2ϩ -and calmodulin-dependent protein kinases are nuclear and therefore qualify as potential SAP155 kinases, i.e. Ca 2ϩ -and calmodulin-dependent protein kinase IV (35) and PSKH1 (36) . Interestingly, PSKH1 shows a dotted nuclear distribution, which could point to an association with the speckles. Further experiments are needed to explore the contribution of a Ca 2ϩ -dependent protein kinase(s) in the phosphorylation of SAP155. It should also be pointed out that Ca 2ϩ -dependent kinases may interfere indirectly with the phosphorylation of SAP155, for example by affecting the activity of Cdks. Thus, it has been reported that Ca 2ϩ -and calmodulindependent protein kinase II phosphorylates and activates Cdc25, which acts as a final trigger for activation of Cdk1 (37) . Finally, we cannot entirely rule out the possibility that the phosphorylation of SAP155 in cell lysates is mediated by a novel type of protein kinase that is inhibited by both EGTA and roscovitine and is activated during mitosis. However, it would be difficult to understand why such a kinase is inhibited more by roscovitine in mitotic lysates than in interphase lysates (Fig. 8) .
In retrospect it is somewhat surprising that we picked up SAP155 as a phosphorylation-dependent interactor of NIPP1 in a yeast dual-hybrid screening since Saccharomyces cerevisiae lacks a NIPP1 homolog and its SAP155 homolog (Hsh155p) lacks a TP-rich domain (38, 39) . Nevertheless, the results of our dual-hybrid screening show that yeast contains a protein kinase(s) that phosphorylates mammalian SAP155 on a site(s) that confers binding to NIPP1.
Role of the NIPP1-SAP155 Interaction-The targeting of NIPP1 to the nuclear speckles (24) and to the spliceosomes (25) is mediated by its FHA domain. This explains why the recruitment of NIPP1 to the spliceosomes in nuclear extracts can be competitively blocked by the addition of an excess of the FHA domain (Fig. 6A) . Mutagenesis studies have revealed that the phosphate-binding loop in the FHA domain is essential for the targeting of NIPP1 to the speckles and to the spliceosomes (24, 25) . Since this phosphate-binding loop is also essential for the interaction of NIPP1 with the splicing factors SAP155 and CDC5L, we speculated that NIPP1 is anchored to the speckles and to the spliceosomes via phosphorylated forms of these splicing factors. Yet a SAP155-derived phosphopeptide that disrupted the interaction between NIPP1 and SAP155 or CDC5L in nuclear extracts did not interfere with the recruitment of NIPP1 to the spliceosomes. These data indicate that NIPP1 is recruited to the spliceosomes independently from SAP155 and CDC5L, which is in agreement with our previous report that SAP155 is recruited at an earlier stage of spliceosome assembly than is NIPP1 (25) . Our finding that the association of NIPP1 with the spliceosomes is disrupted by the addition of the FHA domain but not by one of its phosphorylated ligands also suggests that the FHA domain may contain additional interaction sites for spliceosomal components outside the phosphate-binding loop. An alternative explanation is that the phosphate-binding loop of the FHA domain interacts in the spliceosomes with yet another phosphorylated splicing factor. If the latter could bind to the FHA domain with a much higher affinity than did SAP155 or CDC5L, this could explain our inability to disrupt this complex with the SAP155-derived phosphopeptide.
We can currently only speculate on the possible function of the NIPP1-SAP155 interaction during spliceosome (dis)assembly and splicing catalysis. When the recruitment of NIPP1 to the spliceosomes is prevented, spliceosome assembly is blocked at the transition between the B and C complex (25) . This could indicate that NIPP1 is involved in rearrangements between SAP155 and its interactors at the last stages of spliceosome assembly. In this respect it is worthy to note that, in addition to NIPP1 (this work), also cyclin E (18), U2AF65 (17) , and p14 (16) have been reported to interact with the TP-rich domain of SAP155. It would be interesting to explore whether the interactions with cyclin E, U2AF65, and p14 are also phosphorylationdependent and whether these interactions are affected by the binding of NIPP1.
It is also possible that NIPP1 targets SAP155 or its associated proteins for dephosphorylation by PP1. However, since PP1 does not appear to play an essential role in spliceosome assembly and splicing catalysis in nuclear extracts (25) , we suggest that the dephosphorylation of SAP155 or its associated proteins is rather involved in spliceosome disassembly and/or the targeting of splicing factors to the speckles. By a similar mechanism the increased affinity of SAP155 for NIPP1 (Fig. 8 ) may contribute to the silencing of splicing before mitosis. The proposed substrate-targeting function of NIPP1 is similar to the role of many other non-catalytic subunits of PP1 (40) . Furthermore, it should be pointed out that the dephosphorylation of splicing factors of the SR family by PP1 has also been implicated in spliceosome disassembly and in their shuttling to the speckles (7). Thus, the subnuclear targeting of SR proteins and unrelated splicing factors, such as SAP155, may be regulated by phosphorylation. It is currently unclear which sites of SAP155 may be targeted for dephosphorylation by NIPP1-associated PP1. Obvious candidates are the sites of SAP155 that are phosphorylated during splicing (14) .
In conclusion, we have shown here that NIPP1 interacts in vitro and in vivo with the splicing factor SAP155 and that this interaction is critically dependent on the cell cycle-regulated phosphorylation of specific TP dipeptide sequences in the Nterminal domain of SAP155. Further investigations are needed to explore how the interaction between NIPP1 and SAP155 contributes to spliceosome (dis)assembly and/or the catalytic steps of splicing.
